Comparative Efficacy and Safety of Systemic Steroids, Oral JAK Inhibitors, and Contact Immunotherapy in the Treatment of Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis

    July 2024 in “ Archives of Dermatological Research ”
    Ruixuan Guan, Yiling Lin, Cun Zhang … Yongjun Piao
    Studysummary This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 16

    1. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    2. European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2024
    3. Efficacy and Adverse Effects of Corticosteroid Pulse Therapy in Alopecia Areata Dermatology practical & conceptual · 2023
    4. Alopecia Areata: Current Treatments and New Directions American Journal of Clinical Dermatology · 2023
    5. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    6. Guidelines for the Management of Patients with Alopecia Areata in Korea: Part II Systemic Treatment Annals of Dermatology · 2023
    7. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    8. Autoantigen Discovery in the Hair Loss Disorder, Alopecia Areata: Implications of Post-Translational Modifications Frontiers in immunology · 2022
    9. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    10. The Role of Serum Th1, Th2, and Th17 Cytokines in Patients with Alopecia Areata: Clinical Implications Cells · 2021
    11. Efficacy and Safety of the Oral Janus Kinase Inhibitor Baricitinib in the Treatment of Adults with Alopecia Areata: Phase 2 Results from a Randomized Controlled Study Journal of The American Academy of Dermatology · 2021
    12. A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021
    13. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    14. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm Advances in Therapy · 2017
    15. Diphencyprone and Topical Tacrolimus as Two Topical Immunotherapeutic Modalities: Are They Effective in the Treatment of Alopecia Areata Among Egyptian Patients? A Study Using CD4, CD8, and MHC II as Markers Journal of dermatological treatment · 2010
    16. Topical Immunotherapy of Severe Alopecia Areata with Diphenylcyclopropenone: Experience in an Iranian Population BMC dermatology · 2005

    Related research 3

    1. Serum Zinc Concentration in Patients With Alopecia Areata Acta dermato-venereologica (Print) · 2023
    2. Resistant Alopecia Areata Treated with Tofacitinib International Journal of Trichology · 2022
    3. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018